In a study that aimed to understand the molecular basis of why HDACi respond poorly in solid tumours, the authors found that in breast cancer cells, the feedback activation of the leukemia inhibitory factor receptor (LIFR) signaling, limited the response to HDACi. Here, LIFR is linked to breast carcinoma.